<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01926210</url>
  </required_header>
  <id_info>
    <org_study_id>A-2013-01-05S</org_study_id>
    <nct_id>NCT01926210</nct_id>
  </id_info>
  <brief_title>Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders</brief_title>
  <acronym>POR</acronym>
  <official_title>The Comparison of Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders: a Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huang Rui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized clinical trial to compare the efficiency and safety of mild
      stimulation and controlled ovarian stimulation protocol on the treatment of POR. The
      randomization is achieved on the basis of a computer-generated randomization list in a 1:1
      ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      500 poor ovarian responders will be equally randomized to two different ovarian stimulation
      protocol arms,i.e, mild ovarian stimulation(experimental arm) or controlled ovarian
      stimulation(control arm). In experimental arm, patients will received letrozole 5mg per day
      from cycle day 3 to 7 and recombinant follicle-stimulating hormone (FSH) 150 international
      unit (IU) on day 4 and 6. The dose of recombinant FSH is adjusted according to the ovarian
      response and the gonadotropin-releasing hormone(GnRH)antagonist(Cetrotide) 0.25mg per day is
      administrated when the estradiol level reaches 200 pg/ml and the serum luteinizing hormone
      （LH）level rises above 2 times of basal LH level. In control arm,patients will be stimulated
      with short-acting GnRH agonist long protocol. After complete downregulation is achieved
      through GnRH-agonist, recombinant FSH 300 IU/d is given for 5 days, then the dose of
      recombinant FSH is adjusted according to ovarian response.

      The clinical and ongoing pregnancy rate and other secondary outcome parameters are compared
      between these two groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>live birth rate</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transferrable embryo</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>normal fertilization rate</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of recombinant FSH consumption</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stimulation</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum estradiol level</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum LH level</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum progesterone level</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum FSH level</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSH level in follicular fluid</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LH level in follicular fluid</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol level in the follicular fluid</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progesterone level in follicular fluid</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>testerone level in the follicular fluid</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-müllerian hormone (AMH)level in follicular fluid</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Hyperstimulation Syndrome (OHSS) rate</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>mild ovarian stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlled ovarian stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mild stimulation protocol</intervention_name>
    <description>letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.</description>
    <arm_group_label>mild ovarian stimulation</arm_group_label>
    <other_name>letrozole</other_name>
    <other_name>recombinant FSH</other_name>
    <other_name>GnRH antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>controlled ovarian stimulation</intervention_name>
    <description>After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.</description>
    <arm_group_label>controlled ovarian stimulation</arm_group_label>
    <other_name>GnRH agonist</other_name>
    <other_name>recombinant FSH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a. Poor ovarian responders b. Normal BMI (18-25 Kg/m2) c. Regular menstruation (with
             cycle 23-35 days)

        Exclusion Criteria:

          -  a. History of repeated IVF failure (previous IVF cycle ＞2) b. Serious adenomyosis c.
             Polycystic ovary syndrome(PCOS) patients d. History of allergic to ovulation induction
             medicines e. Abnormal uterine cavity, i.e, intrauterine adhesion f. Attending other
             clinical trials in the same period. g. History of systemic disease contradictory to
             COH or pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>sixth affiliated hospital of Sun Yet-san University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xing Yang, M.D.</last_name>
    <email>yxing8358@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>sixth affiliated hospital of Sun Yet-san University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Deng, M.D.</last_name>
      <email>dengyu1983@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Rui Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2013</study_first_posted>
  <last_update_submitted>August 20, 2013</last_update_submitted>
  <last_update_submitted_qc>August 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huang Rui</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Poor ovarian response</keyword>
  <keyword>in vitro fertilization</keyword>
  <keyword>mild ovarian stimulation</keyword>
  <keyword>controlled ovarian stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

